Media OutReach
Johnson & Johnson and Asia Pacific Patient Advocacy Group Leaders Unite to Strengthen Shared Decision-Making in Lung Cancer Care
J&J deepens its commitment to patient empowerment in Asia Pacific by launching J&J withMe, a new patient portal offering tailored patient resources, and co-driving market-specific initiatives with patient advocacy groups
SINGAPORE – Media OutReach Newswire – 11 December 2025 – Johnson & Johnson announced the next phase of The 3rd Opinion campaign across Asia Pacific, focused on championing shared decision-making between lung cancer patients and healthcare professionals through events and stakeholder engagements at ESMO Asia 2025 in Singapore.
At a Patient Reception on 6th December 2025, 20 leaders from 17 patient advocacy groups from across Asia Pacific, Europe and the United States shared their support for the need to strengthen shared decision-making. On December 7, 2025, the ESMO Asia 2025 Symposium, ‘Advancing EGFRm NSCLC Treatment Through Shared Decision-Making’ highlighted the role of healthcare professionals not only in making sense of the data but also in helping patients and their families navigate complex decision-making.
“High prevalence in Asia of certain NSCLC mutations makes the choice of first-line therapy absolutely critical. Treatment decisions must balance clinical objectives with patient values — weighing disease biology, survival prospects, durable disease control and the tradeoffs of side effects. That’s why shared decision-making is essential: clinicians should present all appropriate treatment options, so the final choice is collaborative and aligned with each patient’s goals,” said Professor Zhu Zhengfei, Director of the Radiation Oncology Department, Fudan University Shanghai Cancer Center.
“When lung cancer patients are empowered to speak up and understand their options, they are more likely to continue the treatment and their dignity is preserved. Initiatives like ‘The 3rd Opinion’ are vital for fostering truly patient-centered partnerships between people living with cancer and their healthcare teams,” noted Ms. Liu Yiting, Marketing & Branding Director, China MeetHealth Mi-Jian Patient Community.
“The shared commitment validates what many people living with lung cancer have long expressed: shared decision making is essential. From our experience supporting patients, meaningful conversations with clinicians help acknowledge patients’ experiences, address their concerns, and preserving their hopes,” added Mr. Jung-Il Cho, Chairman of Korea Lung Cancer Patients Association.
Our commitment comes off the back of a recent patient survey revealing that 90% of Japanese lung cancer patients want to play an active role in their treatment decisions. The survey also found that shared decision-making, where physicians and patients jointly compare treatment options and decide together, is the strongest driver of treatment satisfaction.1
Patient survey finds that those engaged in shared decision-making were 11 times more likely to report higher satisfaction with their treatments, with 90% of lung cancer patients in Japan wanting to play an active role in their treatment decisions. This finding underscores the importance of shared decision-making and patient-centered care.1
To bridge the gap between patients’ desire to engage in shared decision making and their lack of practical support, J&J has launched “J&J withMe”, an online hub that equips lung cancer patients and caregivers with tailored toolkits and conversation guides to prepare for consultations and make informed, personalized treatment decisions.
Anthony Elgamal, Vice President of Oncology, Johnson & Johnson Innovative Medicine Asia Pacific said, “The 3rd Opinion truly puts patients at the center of care. As part of our deep commitment to address patients’ unmet needs, we will continue partnering with patient advocacy groups and healthcare professionals to help patients to find their voice and the moment when medical advice meets what truly matters to patients.”
In recognition of diverse cultural and clinical norms across Asia Pacific, J&J has also rolled out tailored market activations in collaboration with local patient advocacy groups:
- Provision of patient resources such as the “Lung Cancer Book of Answers” in China, ‘Value of Time’ video for patients in Japan, and educational assets in India and Australia/New Zealand;
- Digital and social media engagement featuring patients and creators discussing the importance of shared decision-making across Singapore, Malaysia, Philippines, Thailand, and Vietnam;
- Event engagement via the establishment of a patient advisory board in India;
- Corporate Social Responsibility program with a lung cancer patient group in Korea, bringing employees and patients together to better understand the disease burden of patients and strengthen emotional support for the patient community.
###
About the 3rd Opinion
“The 3rd Opinion”, the patient’s own opinion, is a new term that sparks a social movement in the lung cancer treatment journey – designed to elevate the patient voice and empower individuals to take an active role in shaping their treatment plan. By prioritizing shared decision-making between patients and healthcare professionals, this collaborative approach ensures that treatment choices are aligned to each patient’s goals, preferences and circumstances. This results in more informed decisions, greater patient satisfaction, and the best possible outcomes.
About Non-Small Cell Lung Cancer
Worldwide, lung cancer is one of the most common cancers, with NSCLC making up 80 to 85 percent of all lung cancer cases.[1], [2] The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.[3] Among the most common driver mutations in NSCLC are alterations in EGFR, which is a receptor tyrosine kinase controlling cell growth and division.[4] EGFR mutations are present in 10 to 15 percent of Western patients with NSCLC with adenocarcinoma histology and occur in 40 to 50 percent of Asian patients.[5], [6],[7],[8],[9],[10] EGFR ex19del or EGFR L858R mutations are the most common EGFR mutations.[11] The five-year survival rate for all people with advanced NSCLC and EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs) is less than 20 percent.[12],[13] EGFR exon 20 insertion mutations are the third most prevalent activating EGFR mutation.[14] Patients with EGFR exon 20 insertion mutations have a real-world five-year overall survival (OS) of eight percent in the frontline setting, which is worse than patients with EGFR ex19del or L858R mutations, who have a real-world five-year OS of 19 percent.[15]By comparison, other common cancers, such as breast and prostate cancer have a 5-year real world OS of 90% and 97% respectively[16].
[2] The World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed March 2025.
Hashtag: #Johnson&Johnson
The issuer is solely responsible for the content of this announcement.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Learn more at 
https://www.jnj.com/ or at www.innovativemedicine.jnj.com. Follow us at @JNJInnovMed.
Johnson & Johnson Innovative Medicine Asia Pacific, a division of Johnson & Johnson International (Singapore) Pte. Ltd is a Johnson & Johnson company.
© Johnson & Johnson International (Singapore) Pte. Ltd. [2025] All rights reserved.
We sincerely thank our customers for their continued trust. AIA Hong Kong’s sustained leadership in the number of new business policies reflects that when people seek to protect their own and their loved ones’ future through insurance, AIA’s quality health and wealth solutions — together with services and experiences that go beyond traditional insurance — consistently stand out as their preferred choice.
We remain committed to protecting every moment that matters and helping people and the communities we serve to live Healthier, Longer, Better Lives.
Notes:
* Source: The latest provisional statistics of the Insurance Authority on Hong Kong long-term insurance business from January to September 2025.
** Based on statistics from Insurance Authority released since 2014 – Provisional statistics of the Insurance Authority on Hong Kong long-term insurance business.
Hashtag: #AIAHongKong
The issuer is solely responsible for the content of this announcement.
About AIA Hong Kong & Macau
AIA Group Limited established its operations in Hong Kong in 1931. To date, AIA Hong Kong and AIA Macau have about 18,000 financial planners1, as well as an extensive network of independent financial advisors, brokerage and bancassurance partners. We serve over 3.6 million customers2, offering them a wide selection of professional services and products ranging from individual life, group life, accident, medical and health, pension, personal lines insurance to investment-linked assurance schemes with numerous investment options. We are also dedicated to providing superb product solutions to meet the financial needs of high-net-worth customers.
1 As at 30 June 2025
2 Including AIA Hong Kong and AIA Macau’s individual life, group insurance and pension customers (as at 30 June 2025)
All nominations will undergo a rigorous screening and evaluation process conducted by the VinFuture Pre-Screening Committee and the Prize Council, which comprise leading scientists from around the world, including laureates of prestigious international awards such as the Nobel Prize, the Turing Award, and the Millennium Technology Prize.
The evaluation process is scheduled to be completed by September 2026, with the 6th VinFuture Prize Award Ceremony slated for early December 2026. Nominations submitted after April 17, 2026 will automatically be considered for the 2027 season.
In order to provide comprehensive information and strengthen engagement with its global network of nomination partners, the VinFuture Foundation will host two international webinars in the first quarter of 2026, featuring insights and perspectives from representatives of the Prize Council, the Pre-Screening Committee, and VinFuture Laureates. The first webinar will take place at 8:00 AM on January 26, 2026 (Hanoi time).
In 2026, the VinFuture Prize will continue the implementation of its Top Nominators Recognition Program, formally acknowledging the exceptional contributions of scientists whose discernment and scholarly leadership are instrumental in identifying and nominating scientific and technological achievements of transformative significance for humanity.
Having completed five successive and highly successful award cycles, the VinFuture Prize has established itself as a globally respected distinction within the international science and technology community. To date, it has received a cumulative total of 6,132 nominations from nearly 110 countries and territories and has recognized 48 outstanding scientists whose pioneering work has delivered profound, enduring, and far-reaching benefits to humanity.
Many of the achievements recognized by the VinFuture Prize are closely aligned with major milestones in human progress, ranging from global networking technologies, PERC solar cells, lithium-ion battery energy storage, and artificial intelligence to essential fields such as sustainable agriculture, healthcare, and environmental protection. Reflecting its expanding international reach, VinFuture’s global nomination partner network now includes nearly 15,000 scientists worldwide.
Dr. Thai-Ha Le, Managing Director of the VinFuture Foundation, stated: “After five years of establishment and development, VinFuture Prize has steadily affirmed its position as one of the world’s leading global science prizes, where outstanding scientific excellence is honored in parallel with social responsibility and the long-term interests of humanity. As we enter the 2026 season, we anticipate that nominations will continue to demonstrate the pivotal role of science and technology in addressing global challenges in a comprehensive manner, thereby advancing breakthrough solutions with strong applicability and the capacity to generate positive and sustainable impacts on a global scale.”
With its established international stature and credibility, VinFuture has contributed meaningfully to positioning Viet Nam as an emerging hub for global knowledge exchange and scientific collaboration. Numerous VinFuture partners have traveled to Viet Nam to engage in academic exchanges, share professional expertise, and strengthen ties with the domestic scientific community. Notable participants include Professor Aldo Steinfeld of the Swiss Federal Institute of Technology Zurich (ETH Zurich), recipient of the 2024 SolarPACES Lifetime Achievement Award; Professor Kurt Kremer, Honorary Director of the Max Planck Institute for Polymer Research (Germany); and Professor Chuanbin Mao of The Chinese University of Hong Kong (China), ranked among the world’s top 2% most-cited scientists in biomedical engineering…
Through VinFuture, many Vietnamese scientists have likewise gained access to, and established collaborations with, leading global researchers, actively engaging with the international scientific community to help shape a sustainable future for Vietnam and for humanity at large.
Hashtag: #VinFuture
The issuer is solely responsible for the content of this announcement.
Through this collaboration, FED Fitness and the Houston Rockets aim to bridge professional training standards with the at-home fitness experience, encouraging consistent movement and healthy routines for people of all ages and fitness levels.
FED Fitness offers a wide range of high-quality home exercise equipment, competitive pricing, and a free training app—aligning seamlessly with the Rockets’ performance-driven mindset and community-focused approach to sport and wellness.
Notably, this marks the Houston Rockets’ first partnership with a dedicated home gym solutions brand, reflecting the growing importance of home-based training within the evolving sports and fitness landscape. The partnership also reinforces FED Fitness’s expertise, product quality, and long-term strategic vision, as elite sports organizations increasingly align with innovative home fitness brands.
At the heart of the partnership is a shared commitment to health, discipline, and long-term fitness habits—whether training at home or competing at the highest level on the court.
Extending Professional Training into the Home
FED Fitness operates with the belief that fitness should be accessible, enjoyable, and sustainable, providing solutions designed to support users at different stages of their home fitness journey.
FED Fitness Home Gym Solutions
Its home gym solutions are defined by several core characteristics:
- Professionalgrade equipment
- Home training content system
- Spacefriendly designs
- Scenariodriven content
- Sustainable training system
FED Fitness is more than just equipment treadmills, ellipticals, strength machines, and lightweight accessories. Instead, it goes above and beyond by providing an entire home fitness ecosystem that includes training and health data.
Partnership Benefits for Consumers and Fans
The partnership between FED Fitness and the Houston Rockets is built on a shared focus on training, health, and fitness, as well as a mutual commitment to creating engaging, family-friendly experiences around the game.
Designed to benefit both organizations, the collaboration also delivers added value for Rockets fans through a variety of interactive activations and promotions. These include a sweepstakes for a VIP game experience, home training content featuring FED Fitness products and Houston Rockets personnel, and opportunities for co-branded merchandise offerings. Fans can also follow FED Fitness on social media to access exclusive, fans-only discounts.
About FED Fitness: Brand vision and global health mission
FED Fitness is a global home gym solution brand focused on delivering professional-grade equipment and digital training tools for home use.
Trusted by more than 12 million households worldwide, the brand is committed to helping individuals and families build sustainable fitness habits through accessible, high-quality solutions.
The partnership with the Houston Rockets further reinforces FED Fitness’s long-term vision of integrating professional training standards into home-based fitness and everyday life.
For more information, visit www.fedfitness.com
Hashtag: #FEDFitness
The issuer is solely responsible for the content of this announcement.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism9 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn